1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Blood Cancer United Academic Clinical Trials grant (A Phase 1 Study of Anti-CD64 CAR T Cells in Patients with Venetoclax-refractory Myeloid Neoplasms) is sponsored by Blood Cancer United (formerly The Leukemia & Lymphoma Society). This grant supports a Phase 1 study of anti-CD64 CAR T cells in patients with treatment-resistant acute myeloid leukemia (AML) and related myeloid neoplasms.
The project aims to assess the safety, feasibility, and early efficacy of a novel CAR T-cell therapy developed by CU Anschutz researchers.
Get alerted about grants like this
Save a search for “Blood Cancer United (formerly The Leukemia & Lymphoma Society)” or related topics and get emailed when new opportunities appear.
Search similar grants →According to the current listing, eligibility includes: Research teams and institutions focused on oncology research and clinical trials, specifically for blood cancers. The Gates Institute at University of Colorado Anschutz was awarded this grant. Confirm the full requirements in the official notice before applying.
Blood Cancer United Academic Clinical Trials grant (A Phase 1 Study of Anti-CD64 CAR T Cells in Patients with Venetoclax-refractory Myeloid Neoplasms) is funded by Blood Cancer United (formerly The Leukemia & Lymphoma Society). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Colorado. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Blood Cancer United's Equity in Access Research Program is sponsored by Blood Cancer United (formerly The Leukemia & Lymphoma Society). Generates new evidence to guide policy reform and changes in healthcare practice to mitigate the impact of social, economic, and environmental disadvantages and reduce barriers to care for blood cancer patients and survivors.
A Phase 1 Study of Anti-CD64 CAR T Cells in Patients with Venetoclax-refractory Myeloid Neoplasms is sponsored by Blood Cancer United (formerly The Leukemia & Lymphoma Society). This grant supports a phase 1 clinical trial of a novel CAR T cell therapy developed at the University of Colorado Anschutz, targeting a specific protein (CD64) found on leukemia cells resistant to standard therapies in patients with treatment-resistant acute myeloid leukemia (AML).